Your session is about to expire
← Back to Search
Imaging
Optical Coherence Tomography for Early-Stage Pancreatic Cancer
N/A
Recruiting
Led By Mary Dillhoff, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Immediate surgery cohort: Adult patients with pancreatic cancer or IPMN
Adult patients undergoing pancreatic resection for a presumed IPMN
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Study Summary
This trialtests a new imaging tech to detect small pancreatic cancer in people with the disease. It may help accurately identify cancer in resected tissue.
Who is the study for?
This trial is for adults with pancreatic cancer or intraductal papillary mucinous neoplasm (IPMN) who are scheduled for immediate surgery. Participants must provide informed consent to join the study. Pregnant individuals cannot participate.Check my eligibility
What is being tested?
The study is testing ultra-high resolution optical coherence tomography, a high-tech imaging technique, to see if it can detect very small early-stage pancreatic cancers in tissue removed during surgery.See study design
What are the potential side effects?
Since this trial involves diagnostic imaging and not drug treatment, there are no direct side effects like those associated with medications. However, standard risks of surgical procedures apply.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
Adult patients with pancreatic cancer or IPMN who need surgery right away.
Select...
Adults having surgery to remove a suspected IPMN in the pancreas.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Measure accuracy of using OCT to diagnose pancreatic cancer and compare with histology.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (resection, OCT)Experimental Treatment3 Interventions
Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Optical Coherence Tomography
2016
Completed Phase 2
~1510
Therapeutic Conventional Surgery
2005
Completed Phase 3
~9860
Find a Location
Who is running the clinical trial?
Ohio State University Comprehensive Cancer CenterLead Sponsor
316 Previous Clinical Trials
289,611 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,603 Previous Clinical Trials
40,913,200 Total Patients Enrolled
Mary Dillhoff, MDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Hospital - Wexner Medical Center, Richard M. Ross Heart Hospital
University Of Cincinnati College Of Medicine (Medical School)
1 Previous Clinical Trials
7 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Adult patients with pancreatic cancer or IPMN who need surgery right away.Adults having surgery to remove a suspected IPMN in the pancreas.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (resection, OCT)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants is the clinical trial currently accommodating?
"Affirmative. Clinicaltrials.gov presents evidence that this experiment is currently attempting to recruit participants, with the first post being on March 26th 2019 and the latest edit occurring on November 22nd 2022. In total, 75 individuals are needed from one medical facility."
Answered by AI
Is this research initiative currently seeking participants?
"Clinicaltrials.gov notes that this study is accepting participants, having been first published on March 26th 2019 and most recently revised on November 22nd 2022."
Answered by AI
Share this study with friends
Copy Link
Messenger